{"id":"NCT00093470","sponsor":"National Cancer Institute (NCI)","briefTitle":"Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission","officialTitle":"A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08-18","primaryCompletion":"2015-02-20","completion":null,"firstPosted":"2004-10-08","resultsPosted":"2015-11-10","lastUpdate":"2024-03-20"},"enrollment":144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Adult Acute Megakaryoblastic Leukemia","Adult Acute Monocytic Leukemia","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With Maturation","Adult Acute Myeloid Leukemia With Minimal Differentiation","Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Adult Acute Myeloid Leukemia Without Maturation","Adult Acute Myelomonocytic Leukemia","Adult Erythroleukemia","Adult Pure Erythroid Leukemia","Alkylating Agent-Related Acute Myeloid Leukemia","Myelodysplastic Syndrome With Excess Blasts","Recurrent Adult Acute Myeloid Leukemia"],"interventions":[{"type":"PROCEDURE","name":"Clinical Observation","otherNames":["observation"]},{"type":"DRUG","name":"Tipifarnib","otherNames":["R115777","Zarnestra"]}],"arms":[{"label":"Arm A (tipifarnib)","type":"EXPERIMENTAL"},{"label":"Arm B (clinical observation)","type":"OTHER"}],"summary":"This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone in preventing the recurrence of AML.","primaryOutcome":{"measure":"Disease-free Survival","timeFrame":"Assessed monthly for the first 6 months then every 3 months or as clinically indicated, up to 5 years.","effectByArm":[{"arm":"Arm A (Tipifarnib)","deltaMin":8.87,"sd":null},{"arm":"Arm B (Clinical Observation)","deltaMin":5.26,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.026"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":19,"exclusionCount":null},"locations":{"siteCount":341,"countries":["United States","Israel","Peru"]},"refs":{"pmids":[],"seeAlso":["https://nctn-data-archive.nci.nih.gov/"]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":72},"commonTop":["White blood cell decreased","Anemia","Platelet count decreased","Fatigue","Rash maculo-papular"]}}